Today, 18 July 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) has been approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
Anaphylaxis is a sudden, severe and sometimes life-threatening allergic reaction that causes a drop in blood pressure and breathing difficulties.
Adrenaline is a well-established treatment for anaphylaxis, commonly administered through auto-injectors. This approval marks the introduction of a nasal spray formulation, providing a needle-free alternative for the emergency administration of a potentially life-saving medication.
It is intended for use in adults and children who weigh 30 kg (about 66 pounds) or more.
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:
“Patient safety is our top priority, which is why we’re pleased to approve the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. Until now, adrenaline for self-administration has only been available via auto-injectors.
“We continue to encourage everyone at risk of severe allergic reactions, and those around them, to familiarise themselves with how to respond in an emergency. Resources and guidance are available on the MHRA website to help people be prepared.”
